Clinical Trial

IASO-782 in Systemic Lupus Erythematosus

Name: IASO-782 in Systemic Lupus Erythematosus — clinical trial record (NCT07483346)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

his study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with SLE. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of SLE.

Protocol Amendment History 2 changes

critical Recruitment opened 2026-08-11

notable Trial sites expanded: 0 -> 4 locations 2026-08-11

Trial Details

NCT Number	NCT07483346
Lead Sponsor	Shanghai IASO Biotechnology Co., Ltd
Conditions	SLE - Systemic Lupus Erythematosus
Enrollment	20 participants
Start Date	2026-05-26
Primary Completion	2027-08-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10